Mucoadhesive Film With/without Acmella Oleracea & Triamcinolone Acetonide for Aphthous Ulcers

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-50
SponsorKhon Kaen University

About this trial

The purpose of this study is to evaluate the effectiveness of mucoadhesive film with or without Acmella oleracea extract compared to standard treatment by using 0.1% triamcinolone acetonide in pain relief, promoting wound healing, healing time and satisfaction in 3 aspects included taste, product used and quality of life after using the product.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy participants aged 18-50 years without any underlying diseases.

Participants are voluntary and have signed the informed consent.

Participants are literate.

Participants can follow the treatment guidelines and follow up.

Disqualifiers

Participants with allergies to herbal extracts, Acmella oleracea, or steroids.

Participants with chronic underlying diseases.

Participants with underlying diseases that may affect wound healing.

Participants receiving anti-analgesic drug, systemic steroids, antibiotics, hormones, NSAIDS, or any drugs that affect the oral mucosa.

Trial design

Design model

Parallel

Treatments tested in this trial

  • mucoadhesive film with Acmella oleracea extract

    Other intervention

    Apply 1 patch on ulcer 3 times per day (after meals)

  • Triamcinolone Acetonide 0.1% Oromucosal Paste

    Drug

    Apply ¼ inch on ulcer 3 times per day (after meals)

  • mucoadhesive film without Acmella oleracea extract

    Other intervention

    Apply 1 patch on ulcer 3 times per day (after meals)

Treatment groups

72 Participants
are divided into 3 treatment groups
Group A: mucoadhesive film with Acmella oleracea extractExperimental treatment 1 intervention
Group B: Triamcinolone acetonideActive comparator 1 intervention
Group C: mucoadhesive film without Acmella oleracea extractPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Reduction of ulcer size after using product

Reduction of ulcer size will be evaluated by measuring the diameter of ulcers size using a periodontal probe and photograph on the first day and each follow up visit.

Time frame
Base line, day4, day7, day10 and day 14
2

Pain score

The pain score will be assessed by using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from \"no pain\"(0) to \"worst pain\" (10).The pain level will be recorded on the first day. The participants will then reassess their pain score again after receiving the intervention, which will be evaluated at each follow up visit.

Time frame
Base line, day4, day7, day10 and day 14

Secondary outcomes

1

Satisfaction score

Participants\' satisfaction after using product will be assessed using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from \"unsatisfied\" (0) to \"most satisfied\" (10). Satisfaction will be evaluated on the last day of follow-up.

Time frame
Day 14
2

Quality of life score

Oral health impact on quality of life will be evaluated using the Thai version of the Oral Health Impact Profile-14 (OHIP-14). The survey classified into 7 dimensions with 2 items per dimension included functional limitation, painful, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Participants must choose the answer based on the frequency of problem occurrence. The frequency level is divided into 5 level: never= 0 point, rarely = 1 point, sometimes = 2 points, often = 3 points, always = 4 points. Total scores in each person range are between 0 to 56 points.The quality of life will be survey on the first and the last day of follow-up.

Time frame
base line and day 14

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Khon Kaen University

Lead sponsor

National Institute of Dental and Craniofacial Research (NIDCR)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: